ES2116290T3 - 2(5h)-furanonas sustituidas en posicion 3, como antagonistas del canal del ca2+ y agentes anti-inflamatorios. - Google Patents

2(5h)-furanonas sustituidas en posicion 3, como antagonistas del canal del ca2+ y agentes anti-inflamatorios.

Info

Publication number
ES2116290T3
ES2116290T3 ES91907515T ES91907515T ES2116290T3 ES 2116290 T3 ES2116290 T3 ES 2116290T3 ES 91907515 T ES91907515 T ES 91907515T ES 91907515 T ES91907515 T ES 91907515T ES 2116290 T3 ES2116290 T3 ES 2116290T3
Authority
ES
Spain
Prior art keywords
substituted
arylalkyl
alkyl
inflammatory agents
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91907515T
Other languages
English (en)
Inventor
Gary C M Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ES2116290T3 publication Critical patent/ES2116290T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/58—One oxygen atom, e.g. butenolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring

Abstract

SE PRESENTAN COMPUESTOS DE LA FORMULA (I) EN LA QUE R ES ALQUIL, ARALQUIL O ARILALQUIL SUBSTITUIDO, O ALQUENIL QUE CONTIENE UNO O MAS ENLACES OLEFINICOS; X ES O, NH O NR1, DONDE R1 ES ALQUIL DE ENTRE 1 Y 20 ATOMOS DE CARBONO O ARALQUIL; E Y ES H, ALQUIL DE ENTRE 1 Y 20 ATOMOS DE CARBONO, ARALQUIL, ARIL, ARIL SUBSTITUIDO, ARILALQUIL SUBSTITUIDO, ALQUENIL CONTENIENDO UNO O MAS ENLACES OLEFINICOS, PO(0H)2, PO(OH)OR2, PO(OH)R2, PO(OR2)2, DONDE R2 ES INDEPENDIENTEMENTE ALQUIL DE ENTRE 1 Y 20N ATOMOS DE CARBONO, FENIL O FENIL SUBSTITUIDO, ADEMAS Y ES CO-R3, CO-OR3, CONHR3, SO2R3, SO2NHR3, (CH2)-O-R3, O (CH2)N-O-(CH2)M-OR3, DONDE N, Y M, SON ENTEROS Y VALEN INDEPENDIENTEMENTE ENTRE 1 Y 20 Y R3 ES H, ALQUIL, ALQUENIL CONTENIENDO UNO O MAS ENLACES OLEFINICOS, ARIL, ARIL SUBSTITUIDO, ARILALQUIL O ARILALQUIL SUBSTITUIDO, CON LA CONDICION DE QUE CUANDO Y SEA CO-R3, CO-OR3 Y CONHR3, ENTONCES R3 NO SERA HIDROGENO. LOS COMPUESTOS SON ANTAGONISTAS DEL CANAL CA2+, TIENEN POCA O NINGUNA ACTIVIDAD COMO INHIBIDORES DE LA FOSFOLIPASA A2, Y SON AGENTES ANTIINFLAMATORIOS.
ES91907515T 1990-04-17 1991-03-25 2(5h)-furanonas sustituidas en posicion 3, como antagonistas del canal del ca2+ y agentes anti-inflamatorios. Expired - Lifetime ES2116290T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/510,367 US5043457A (en) 1990-04-17 1990-04-17 2(5H)-furanones substituted in the 3 position, as Ca2+ channel antagonists and anti-inflammatory agents

Publications (1)

Publication Number Publication Date
ES2116290T3 true ES2116290T3 (es) 1998-07-16

Family

ID=24030459

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91907515T Expired - Lifetime ES2116290T3 (es) 1990-04-17 1991-03-25 2(5h)-furanonas sustituidas en posicion 3, como antagonistas del canal del ca2+ y agentes anti-inflamatorios.

Country Status (9)

Country Link
US (1) US5043457A (es)
EP (1) EP0525002B1 (es)
JP (1) JPH05506024A (es)
AT (1) ATE165972T1 (es)
CA (1) CA2078770A1 (es)
DE (1) DE69129408T2 (es)
ES (1) ES2116290T3 (es)
IE (1) IE911266A1 (es)
WO (1) WO1991016048A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171863A (en) * 1987-06-08 1992-12-15 Allergan, Inc. Intermediates for preparing 4-substituted 2-5(H)-furanones as anti-inflammatory agents
US5134128A (en) * 1987-06-08 1992-07-28 Allergan, Inc. Anti-inflammatory furanones
US5089485A (en) * 1988-11-18 1992-02-18 Allergan, Inc. Anti-inflammatory furanones
US5045564A (en) * 1988-12-07 1991-09-03 Allergan, Inc. Anti-inflammatory 2-furanones
US5112853A (en) * 1989-11-20 1992-05-12 Allergan, Inc. Anti-inflammatory furanone compounds
US5258400A (en) * 1989-11-20 1993-11-02 Allergan, Inc. Anti-inflammatory furanone compounds
US5183906A (en) * 1991-04-30 1993-02-02 Allergan, Inc. 2- and 5-alkyl and phenyl substituted 4-(1-hydroxy, 1-acyloxy or 1-carbamoyloxy)-5-hydroxy-2 (5h)-furanones as anti-inflammatory agents
US5225571A (en) * 1991-04-30 1993-07-06 Allergan, Inc. Substituted dihydroxy-bis-[5-hydroxy-2(5H)-furanone-4-yl]-alkanes as anti-inflammatory agents
US5169963A (en) * 1991-08-30 1992-12-08 Allergan, Inc. Di-(5-hydroxy-2(5H)2-oxo-4-furyl)alkylmethyl-alpha,omega alkanedioates and N,N-bis-(5-hydroxy-2(5H)2-oxo-4-furyl)alkylmethyl-alpha,omega-dialkanoic acid amides as anti-inflammatory agents
US5171864A (en) * 1991-08-30 1992-12-15 Allergan, Inc. Di-(5-hydroxy-2(5H)-2-oxo-4-furyl)methyl-alpha,omega alkane-dioates and N,N-bis-(5-hydroxy-2(5H)-2-oxo-4-furyl)methyl-alpha,omega-dialkanoic acid amides as anti-inflammatory agents
US5268387A (en) * 1992-04-24 1993-12-07 Allergan, Inc. Pharmaceutical compositions and method for administering 3 and 4-substituted 2(5H)-furanones to a mammal for inhibiting bone loss
US5451686A (en) * 1994-04-15 1995-09-19 Allergan, Inc. 3 and 5 alkyl and phenyl 4-(hydroxy or acyloxy)-alkyl substituted 2(5H)-furanones as anti-inflammatory agents
DE60234057D1 (de) 2001-07-25 2009-11-26 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
EP1560915B1 (en) * 2002-10-10 2009-03-04 Merck & Co., Inc. Assay methods for state-dependent calcium channel agonists/antagonists
SI1889198T1 (sl) 2005-04-28 2015-02-27 Proteus Digital Health, Inc. Farma-informacijski sistem
MX2009002893A (es) 2006-09-18 2009-07-10 Raptor Pharmaceutical Inc Tratamiento de trastornos hepaticos mediante la administracion de conjugados de la proteina asociada al receptor (rap).
WO2010095940A2 (en) 2009-02-20 2010-08-26 To-Bbb Holding B.V. Glutathione-based drug delivery system
NZ596876A (en) 2009-05-06 2014-01-31 Lab Skin Care Inc Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2359096A (en) * 1941-03-21 1944-09-26 Lilly Co Eli beta-substituted-delta alpha, beta-gamma-butyrolactones and beta-substituted - beta - hydroxy-gamma-butyrolactones and methods of preparing them
US2359208A (en) * 1941-03-21 1944-09-26 Lilly Co Eli beta-substituted-delta alpha,beta-gamma-butyrolactones and beta-substituted-beta-hydroxy-gamma-butyrolactones and the methods of preparing them
US4447455A (en) * 1980-12-01 1984-05-08 Madaus And Company Oral urolithiasis remedy
US4616089A (en) * 1983-08-03 1986-10-07 University Of California Synthetic anti-inflammatory derivatives of manoalide
DE3472958D1 (en) * 1983-08-03 1988-09-01 Univ California Synthetic analgesic and/or anti-inflammatory derivatives of manoalide
JPS6058973A (ja) * 1983-09-13 1985-04-05 Mitsubishi Yuka Yakuhin Kk γ−プチロラクトン誘導体及びそれを有効成分とする免疫調節剤
US4789749A (en) * 1984-06-18 1988-12-06 The Regents Of The University Of California Manoalide analogs
ZA864674B (en) * 1985-07-01 1988-02-24 Lilly Co Eli Furanone derivatives
US4786651A (en) * 1986-02-03 1988-11-22 Allergan, Inc. Treatment of cutaneous hyperproliferative dermatoses with manoalide
DE3615157A1 (de) * 1986-05-05 1987-11-12 Schwabe Willmar Gmbh & Co 5-arylalkyl-4-alkoxy-2(5h)-furanone, zwischenprodukte und verfahren zu ihrer herstellung sowie ihre anwendung als therapeutische wirkstoffe
CA1329390C (en) * 1987-06-08 1994-05-10 John N. Bonfiglio Anti-inflammatory furanones
US4916241A (en) * 1988-06-06 1990-04-10 American Home Products Corporation Inhibition of bone loss by 4-substituted-5-hydroxy-2(5H)-furanones
US4935530A (en) * 1988-10-18 1990-06-19 Allergan, Inc. Process for preparing 5-substituted-3-furaldehydes
US4957917A (en) * 1989-10-25 1990-09-18 Allergan, Inc. Anti-inflammatory furanones
US5013850A (en) * 1990-03-30 1991-05-07 Allergan, Inc. 4-ethyl and 4-ethenyl-5-hydroxy-2(5H)-furanones substituted on alpha carbon of the ethyl or ethenyl side chain with a long chain alkyl group and on the beta carbon with a polar group, as anti-inflammatory agents

Also Published As

Publication number Publication date
CA2078770A1 (en) 1991-10-18
DE69129408T2 (de) 1998-09-03
DE69129408D1 (de) 1998-06-18
IE911266A1 (en) 1991-10-23
ATE165972T1 (de) 1998-05-15
EP0525002A1 (en) 1993-02-03
US5043457A (en) 1991-08-27
EP0525002B1 (en) 1998-05-13
WO1991016048A1 (en) 1991-10-31
JPH05506024A (ja) 1993-09-02
EP0525002A4 (en) 1993-03-10

Similar Documents

Publication Publication Date Title
ES2116290T3 (es) 2(5h)-furanonas sustituidas en posicion 3, como antagonistas del canal del ca2+ y agentes anti-inflamatorios.
ES483311A1 (es) Un procedimiento para preparar derivados de prolina
AR247213A1 (es) Preparacion de acido 7-¡(1-carboxi-3-fenilpropil)amino¿-3,4,6,7,8,12b-octahidro-6-oxopirido ¡2,1-a¿ o hexahidro-6-oxo-1h(1,4-tiazino¡3,4-a¿¡2¿-benzazepin-4-carboxilico, agentes hipertensivos.
AU557691B2 (en) 2-penem antibiotics and their oxa-aza-, and carba analogues
ATE69817T1 (de) Tetraoxodiazabicyclo-(3,3,1)-nonane.
NZ195992A (en) 5-halopyrimidines;their 2-sulphides and s-oxides;pharmaceutical compositions
ES465384A1 (es) Procedimiento para la obtencion de ciclopentan-1-aminas
SE7601143L (sv) Nytt oxadiazolinonderivat
FR2362892A1 (fr) Compositions polymeres vulcanisables contenant des derives d'hydantoine
DE3875346D1 (de) Zusammensetzungen, die mit 1-oxo- oder thiokohlenwassserstoff substituierte azacycloalkane enthalten.
ZA816259B (en) 2-(1,4-benzodioxan-2-ylalkyl)imidazoles useful as antidepressants
ES545575A0 (es) Un procedimiento para la preparacion de tiazolidinas
ES2070623T3 (es) Oxisulfonilureas inhibidoras de acat.
ES477785A1 (es) Procedimiento para la preparacion de nuevas 2-fenilimino- imidazolidinas sustituidas.
ES455741A1 (es) Un procedimiento para la preparacion de nuevos derivados de 1,3-bencenodimetanol.
ES469613A1 (es) Procedimiento para la obtencion de compuetos de fenilaceta- mida
ES481551A1 (es) Procedimiento de preparacion de nuevos compuestos bis (ari- loxicarboxilicos).
ES8200648A2 (es) Procedimiento de preparacion de compuestos opacificantes para radiografia y similares
ES8702379A1 (es) Un procedimiento para la produccion de 1h-tetrazol-5-carboxamidas-n-sustituidas.
FI823458A0 (fi) Substituerade tiazolidinylestrar av mineralsyror
ES8401456A1 (es) Procedimiento para la preparacion de 2-aminometilfenoles.
ES451762A1 (es) Procedimiento para la obtencion de esteres de acidos fosfo- ricos.
KR970706280A (ko) 5-HT1A 길항제로서의 비사이클릭 카복스아미드(Bicyclic carboxamides as 5-HT1 antagonists)
FI852036A0 (fi) Foerfarande foer framstaellning av nya resorcinetrar.
ES458818A1 (es) Procedimiento para la produccion de derivados de benzofura- no.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 525002

Country of ref document: ES